Compugen LtdCGEN

Compugen Ltd, the Israeli clinical-stage drug discovery company, quietly filed its annual 20-F on 18 May 2026, reporting $72.8 million in revenue, $35.3 million in net income, and $90.6 million in cash and cash equivalents at 31 December 2025. These are not the numbers of a company in crisis; they are the numbers of a company running a lean operation while waiting for its pipeline to graduate from slides to syringes. The company’s predictive computational discovery platform is now seven years old, yet Compugen still lacks an FDA-approved therapy, making the balance sheet’s solidity a statement of discipline rather than a signal of imminent product launch.

Compugen describes itself as a clinical-stage drug discovery and development outfit that uses a predictive computational platform to identify novel drug targets, new biological pathways, and to develop cancer immunotherapies. Its public materials stress the platform and its potential, but the filings stress the cash runway. The company’s website hosts quarterly results, press releases, and proxy statements under a banner that promises “From Code to Cure®”, a slogan that sounds heroic until you notice the asterisk-no asterisk needed, because the code is here, the cure is not.

For the year to 31 December 2025, Compugen reported revenue of $72.8 million (20-F), net income attributable to parent of $35.3 million, operating income of $31.3 million, and diluted EPS of $0.38 on 93.8 million diluted shares. Cash and cash equivalents stood at $90.6 million, while operating cash flow was $31.6 million. The company spent just $306,000 on property, plant, and equipment, confirming that this is a brain-and-server business, not a brick-and-mortar one. R&D expense was $22.8 million, a figure that dwarfs the capital-light capex and underscores the binary nature of the company’s economics: spend on science today, collect on science tomorrow, or not.

The company’s most recent quarterly update is a 6-K filed on 18 May 2026 announcing first quarter 2026 results; the release is available on the company’s investor site and via SEC EDGAR. The SEC’s company facts JSON feed for CIK 0001119774 provides structured XBRL data for the same period. All filings and exhibits are also available on the company’s own website, a transparency choice that feels both generous and necessary given the absence of a marketed product. The company’s SEC submissions JSON feed confirms the filing cadence, but it does not confirm product approvals or revenue durability beyond existing partnerships.

There is The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The company has not supplied a dedicated investor-relations chart pack, nor has it published an investor presentation with clinical timelines. What it has supplied is a clean balance sheet, a modest burn, and a promise that code will one day become cure. Whether markets reward patience or punish diligence remains, for now, a matter of faith rather than filing.

Compugen’s story is not one of failure; it is a story of disciplined spending against a long horizon. The company’s cash runway is long enough to fund multiple discovery programmes, but short enough that management cannot afford to miss its next inflection. The board’s decision to appoint a U.S. process agent in the F-3 registration suggests that Delaware, not Tel Aviv, is the jurisdiction where the company expects its next act to play out. The optics are neat, the cash is real, and the slogan is slick. The missing piece is a single human trial readout that moves the pipeline from slide to syringe-and until that happens, the balance sheet is the main event.